The Premier group purchasing organization will launch a limited-time promotion of Siemens ultrasound scanners beginning this month and running through September. The program will include special financing programs and extended discounts on Sonoline
The Premier group purchasing organization will launch a limited-time promotion of Siemens ultrasound scanners beginning this month and running through September. The program will include special financing programs and extended discounts on Sonoline scanners manufactured by the Issaquah, WA, vendor. Siemens said the promotion was the first of its kind since several GPOs merged in 1995 to form the new Premier. Siemens and Premier signed a three-year ultrasound purchasing and service deal earlier this year.
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Month, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Appealing Prior Authorization Denials: Can it be Effective for Emerging Technologies?
May 14th 2024While radiologists and other providers may be discouraged by insurer denials saying the use of a technological advance is “unproven and investigational,” 82 percent of appeals for prior authorization denials were approved in 2021.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.